Pluri Inc

NASDAQ:PLUR

4.94

-0.20 (-3.96%)

4:48:35 PM EDT: $4.88 -0.06 (-1.15%)

Market Cap (Intraday)	38.67M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.4 Million
Adjusted EPS	-$0.73

See more estimates

10-Day MA	$4.94
50-Day MA	$5.10
200-Day MA	$4.73

See more pivots

Pluri Inc Stock, NASDAQ:PLUR

MATAM Advanced Technology Park, Building No. 5, Haifa, Haifa 3508409

Israel

Phone: +972.74.710.8600

Number of Employees: 118

http://www.pluri-biotech.com

Description

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.